322 related articles for article (PubMed ID: 31313530)
1. Treatment of pediatric pulmonary arterial hypertension: A focus on the NO-sGC-cGMP pathway.
Beghetti M; Gorenflo M; Ivy DD; Moledina S; Bonnet D
Pediatr Pulmonol; 2019 Oct; 54(10):1516-1526. PubMed ID: 31313530
[TBL] [Abstract][Full Text] [Related]
2. The nitric oxide-soluble guanylate cyclase-cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase.
Benza RL; Grünig E; Sandner P; Stasch JP; Simonneau G
Eur Respir Rev; 2024 Jan; 33(171):. PubMed ID: 38508664
[TBL] [Abstract][Full Text] [Related]
3. Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP?
Koress C; Swan K; Kadowitz P
Curr Hypertens Rep; 2016 Apr; 18(5):42. PubMed ID: 27118316
[TBL] [Abstract][Full Text] [Related]
4. Soluble guanylate cyclase stimulators in pulmonary hypertension.
Stasch JP; Evgenov OV
Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
[TBL] [Abstract][Full Text] [Related]
5. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA
Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774
[TBL] [Abstract][Full Text] [Related]
6. Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Dasgupta A; Bowman L; D'Arsigny CL; Archer SL
Clin Pharmacol Ther; 2015 Jan; 97(1):88-102. PubMed ID: 25670386
[TBL] [Abstract][Full Text] [Related]
7. Discovery and development of sGC stimulators for the treatment of pulmonary hypertension and rare diseases.
Sandner P; Becker-Pelster EM; Stasch JP
Nitric Oxide; 2018 Jul; 77():88-95. PubMed ID: 29738821
[TBL] [Abstract][Full Text] [Related]
8. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
Pradhan K; Sydykov A; Tian X; Mamazhakypov A; Neupane B; Luitel H; Weissmann N; Seeger W; Grimminger F; Kretschmer A; Stasch JP; Ghofrani HA; Schermuly RT
Int J Cardiol; 2016 Aug; 216():85-91. PubMed ID: 27140341
[TBL] [Abstract][Full Text] [Related]
9. Soluble Guanylate Cyclase Stimulators and Activators: Where are We and Where to Go?
Xiao S; Li Q; Hu L; Yu Z; Yang J; Chang Q; Chen Z; Hu G
Mini Rev Med Chem; 2019; 19(18):1544-1557. PubMed ID: 31362687
[TBL] [Abstract][Full Text] [Related]
10. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure.
Breitenstein S; Roessig L; Sandner P; Lewis KS
Handb Exp Pharmacol; 2017; 243():225-247. PubMed ID: 27900610
[TBL] [Abstract][Full Text] [Related]
11. The Impact of the Nitric Oxide (NO)/Soluble Guanylyl Cyclase (sGC) Signaling Cascade on Kidney Health and Disease: A Preclinical Perspective.
Krishnan SM; Kraehling JR; Eitner F; Bénardeau A; Sandner P
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890734
[TBL] [Abstract][Full Text] [Related]
12. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
Hoeper MM; Al-Hiti H; Benza RL; Chang SA; Corris PA; Gibbs JSR; Grünig E; Jansa P; Klinger JR; Langleben D; McLaughlin VV; Meyer GMB; Ota-Arakaki J; Peacock AJ; Pulido T; Rosenkranz S; Vizza CD; Vonk-Noordegraaf A; White RJ; Chang M; Kleinjung F; Meier C; Paraschin K; Ghofrani HA; Simonneau G;
Lancet Respir Med; 2021 Jun; 9(6):573-584. PubMed ID: 33773120
[TBL] [Abstract][Full Text] [Related]
13. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
Lian TY; Jiang X; Jing ZC
Drug Des Devel Ther; 2017; 11():1195-1207. PubMed ID: 28458514
[TBL] [Abstract][Full Text] [Related]
14. Soluble Guanylate Cyclase Stimulators and Activators.
Sandner P; Zimmer DP; Milne GT; Follmann M; Hobbs A; Stasch JP
Handb Exp Pharmacol; 2021; 264():355-394. PubMed ID: 30689085
[TBL] [Abstract][Full Text] [Related]
15. Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension.
Ghofrani HA; Humbert M; Langleben D; Schermuly R; Stasch JP; Wilkins MR; Klinger JR
Chest; 2017 Feb; 151(2):468-480. PubMed ID: 27263466
[TBL] [Abstract][Full Text] [Related]
16. [The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat].
Gratsianskaya SE; Valieva ZS; Martynyuk TV
Ter Arkh; 2020 Oct; 92(9):77-84. PubMed ID: 33346435
[TBL] [Abstract][Full Text] [Related]
17. Riociguat for the treatment of pulmonary hypertension.
Schermuly RT; Janssen W; Weissmann N; Stasch JP; Grimminger F; Ghofrani HA
Expert Opin Investig Drugs; 2011 Apr; 20(4):567-76. PubMed ID: 21391889
[TBL] [Abstract][Full Text] [Related]
18. Erectile Dysfunction in Heme-Deficient Nitric Oxide-Unresponsive Soluble Guanylate Cyclase Knock-In Mice.
Decaluwé K; Pauwels B; Boydens C; Thoonen R; Buys ES; Brouckaert P; Van de Voorde J
J Sex Med; 2017 Feb; 14(2):196-204. PubMed ID: 28161078
[TBL] [Abstract][Full Text] [Related]
19. From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators.
Sandner P
Biol Chem; 2018 Jun; 399(7):679-690. PubMed ID: 29604206
[TBL] [Abstract][Full Text] [Related]
20. The Endothelium-Dependent Nitric Oxide-cGMP Pathway.
Mónica FZ; Bian K; Murad F
Adv Pharmacol; 2016; 77():1-27. PubMed ID: 27451093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
